Brief: TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
15/04/2024 14:05
April 15 (Reuters) - Transcode Therapeutics Inc
RNAZ.O :
* TRANSCODE THERAPEUTICS ANNOUNCES FDA CLEARANCE TO INITIATE
PHASE
1/2 CLINICAL TRIAL WITH TTX-MC138 IN PATIENTS WITH ADVANCED
SOLID TUMORS
Source text for Eikon: ID:nGNX1GzNFv
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors